Dietary cholesterol intake has only a weak, variable effect on blood cholesterol levels.
7 events · 3 assessments · 3 decisions
Reassessed
Triggered by subclaim_change: the supporting subclaim "dietary cholesterol intake suppresses endogenous cholesterol synthesis" was assessed for the first time as VERIFIED (0.9), with a caveat that compensation is partial/modest and also involves reduced absorption and increased excretion. This finding is fully consistent with the parent's prior SUPPORTED verdict and is absorbed without a status change: it firms up the mechanistic explanation for the small net average effect ("weak"), and the partial-compensation caveat matches "weak but nonzero" rather than contradicting it. Both supporting subclaims (hyper-responders SUPPORTED; synthesis suppression now VERIFIED) are now assessed and confirmed, so confidence nudged 0.74 -> 0.76; status remains SUPPORTED because "weak" is a defensible-but-contestable framing the AHA qualifies at high doses. No structural changes: existing decomposition (two supporting subclaims, one affirming instance) still captures what the claim turns on; no missing dependency discovered. Light pass appropriate given modest, absorbable materiality on a well-established claim. Importance left at 0.55 (major nutrition/guidelines claim, moderately contested). No named arguments to evaluate. Parent status unchanged, so no dependent notification needed.
Reassessed: still Supported
verdict confidence 0.74 → 0.76 · credence 0.80
Reassessed (status unchanged), set importance
Trigger: subclaim_change on the hyper-responder subclaim (first assessment SUPPORTED, conf 0.82, credence 0.87). Reviewed full context: two supporting subclaims (endogenous-synthesis suppression, and hyper-responder subset), one affirming instance, no arguments. The change is a supporting subclaim being confirmed and is fully consistent with the parent's prior verdict, so it is absorbed without a status change (§22). It marginally strengthens the "variable" descriptor and, via its noted soft edge (hyper-responders raise LDL and HDL together, ratio unchanged), reinforces the clinically-relevant reading of "weak." Nudged confidence 0.72 -> 0.74; kept status SUPPORTED and credence 0.8. No structural change: existing decomposition (synthesis-suppression mechanism + hyper-responder variability) still captures what the claim turns on; no missing dependency found. Set importance to 0.55 (major-tier, moderate contestation 0.5): load-bearing for the egg/CVD and guideline-cap cluster and actively discussed, but the isolated dietary-cholesterol effect is a fairly settled and narrow node. No new web search: the change did not raise new evidentiary questions the standing assessment had not already weighed (AHA advisory, Vincent 2019, feeding-study pooling). Not notifying dependents: status and credence are materially unchanged, so no dependent could reasonably need re-judging.
Reassessed: still Supported
verdict confidence 0.72 → 0.74 · credence 0.80
Structured and assessed
First pass. Decomposition: the Matcher flagged my proposed quantitative "magnitude" subclaim (100 mg/day → few mg/dL) as identical to this parent claim, so I did not duplicate it — the magnitude IS the claim. For the "variable" descriptor I linked the existing claim about hyper-responders (099fc023) as SUPPORTS rather than minting a near-duplicate general variability claim. I created one novel mechanistic subclaim (dietary cholesterol suppresses endogenous synthesis, importance 0.35) to carry the physiological basis for the "weak" average effect. No named argument created — a single natural supporting line, transparent without grouping. Importance set to 0.5 (notable/major: publicly consulted, drove the 2015 guideline change, but the narrow blood-cholesterol proposition is fairly settled). Assessed SUPPORTED (confidence 0.72, credence 0.8): feeding studies (~2 mg/dL per 100 mg), documented responder variability, and homeostatic compensation support it; the AHA's emphasis on larger effects at high doses and in susceptible groups is the credible qualification that keeps it short of VERIFIED, since "weak" carries an interpretive threshold.
Assessed Supported
verdict confidence 0.72 · credence 0.80
Controlled feeding studies find that dietary cholesterol raises blood cholesterol by only a small amount per unit consumed: pooling of roughly 160 feeding trials puts the increase at about 2 mg/dL of total cholesterol (close to 2 mg/dL of LDL) for each additional 100 mg/day, a change most reviewers regard as modest. The response is also markedly uneven across people. A substantial minority (often estimated at around a third of the population) are "hyper-responders" whose cholesterol rises appreciably, while "hypo-responders" show little or no change, a heterogeneity the National Lipid Association describes as marked inter-individual variability. A homeostatic mechanism helps explain the small average effect: when cholesterol intake rises, the body tends to reduce its own endogenous synthesis. This body of evidence is what led the 2015 US Dietary Guidelines to drop their longstanding 300 mg/day limit. The main qualification concerns the word "weak." At high intakes the effect is larger: a meta-analysis of intervention trials feeding 500 to 1400 mg/day reported an LDL increase near 7 mg/dL, and dose-response analyses find the relationship is real and roughly dose-dependent rather than absent. The American Heart Association accordingly continues to advise moderating cholesterol intake and stresses that the effect is genuine, not negligible, particularly for hyper-responders and people with diabetes. The disagreement is therefore less about the underlying numbers, which are broadly agreed, than about whether an average per-unit effect of a few mg/dL and a strongly variable individual response should be summarized as "weak." On that framing the mainstream characterization supports the claim, while a minority would emphasize the effect more strongly.
Claim entered the graph